What We're Reading: Page 113
Industry reads hand-picked by our editors
Aug 30, 2022
-
Science
Scientists question Moderna invention claim in COVID-19 vaccine dispute
-
The Boston Globe
Despite industry-wide stock slump, Mass biotech startups raised $5.1 billion in the first half of 2022
-
BioCentury
It’s not a fraternity anymore
-
Endpoints News
China’s DNA giant confronts skepticism in US expansion bid
Aug 29, 2022
-
STAT
For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career
-
The New York Times
How to Get Heart Patients to Take Their Pills? Give Them Just One.
-
Chemical & Engineering News
Drug developers look to lysine on disease-linked proteins
-
The Wall Street Journal
Latest Covid Boosters Are Set to Roll Out Before Human Testing Is Completed
Aug 26, 2022
Aug 25, 2022
Aug 24, 2022
-
Axios
Democrats’ drug pricing law puts cancer drugs in the spotlight
-
Bloomberg
Pfizer Bidding War With J&J Preceded Global Blood Therapeutics Deal
-
The New York Times
Biden Administration Plans for Booster Shot Campaign in September
-
Endpoints News
Bluebird’s regulatory chief departed two days after historic gene therapy nod to join Flagship’s Tessera
Aug 23, 2022
-
Reuters
AstraZeneca on hunt for acquisitions - CEO
-
The Wall Street Journal
IPO Market Faces Worst Year in Two Decades. ‘Really Hard Pill to Swallow.’
-
San Francisco Business Times
Behind the scenes of Pfizer’s $5.4 billion buyout of Global Blood Therapeutics
-
STAT
Unlikely protein implicated in mouse study using ALS patients’ spinal fluid
Aug 22, 2022
-
The Wall Street Journal
Biotech Rebounds on Optimism and Deal Making
-
Evaluate Vantage
Esmo 2022 preview: front-line liver cancer showdown
-
The Washington Post
Amid covid surge, Iran cut corners to approve yet-unproven vaccine
-
Reuters
Meagre medicine cabinet leaves Sanofi unloved
Previous
